Fisher Asset Management LLC Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Fisher Asset Management LLC grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 414,719 shares of the biopharmaceutical company’s stock after purchasing an additional 90,714 shares during the quarter. Fisher Asset Management LLC’s holdings in Halozyme Therapeutics were worth $19,828,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Halozyme Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after purchasing an additional 30,901 shares during the period. Boston Trust Walden Corp boosted its stake in shares of Halozyme Therapeutics by 28.0% during the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock valued at $41,790,000 after purchasing an additional 191,465 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Halozyme Therapeutics by 6.2% during the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after purchasing an additional 31,871 shares during the period. Glenmede Trust Co. NA boosted its stake in shares of Halozyme Therapeutics by 28.9% during the third quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company’s stock valued at $27,883,000 after purchasing an additional 109,283 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Halozyme Therapeutics by 1.4% during the fourth quarter. Rhumbline Advisers now owns 410,508 shares of the biopharmaceutical company’s stock valued at $19,626,000 after purchasing an additional 5,833 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HALO has been the subject of a number of recent analyst reports. Benchmark reissued a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Finally, Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Down 2.0 %

NASDAQ:HALO opened at $57.96 on Tuesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The stock has a market capitalization of $7.14 billion, a P/E ratio of 16.90, a P/E/G ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company’s 50-day simple moving average is $54.53 and its 200-day simple moving average is $54.72.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares of the company’s stock, valued at $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 31,697 shares of company stock worth $1,754,451. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.